US Patent

US8022054 — Liquid ganaxolone formulations and methods for the making and use thereof

Formulation · Assigned to Marinus Pharmaceuticals Inc · Expires 2026-11-28 · 1y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects liquid formulations of ganaxolone with stable particles having a volume-weighted median diameter of 50-500 nanometers.

USPTO Abstract

In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.

Drugs covered by this patent

Patent Metadata

Patent number
US8022054
Jurisdiction
US
Classification
Formulation
Expires
2026-11-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Marinus Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.